EPCAM and cancer: The results of in vivo testing demonstrated that EpCAM + CD133 − cancer stem cells are more resistant to treatment using LDL nanoparticles packed with docosahexaenoic acid compared to EpCAM − CD133 − adult cancer cells [266].